US-based Adimab has partnered with GlaxoSmithKline (GSK) to develop a custom library, which will be used by GSK to generate bispecific antibody leads.
The collaboration was based on Adimab’s first platform technology transfer and license agreement, which was signed with GSK in 2013.
Go deeper with GlobalData
Adimab co-founder Tillman Gerngross said: "The Adimab platform can identify highly specialised functional IgGs, and incorporate them rapidly into stable, well-expressing bispecific leads.
"Further, the Adimab platform is a protein engineering tool that allows us to optimise molecules in virtually any bispecific format."
Adimab will also use the library, as well as its existing technology in collaboration with GSK, to discover antibodies against multiple targets and generate bispecific antibodies against combinations of those targets.
Under the deal, Adimab will transfer the library to GSK for its internal use in the discovery of bispecifics.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn addition, the deal provides GSK with the right to develop and commercialise therapeutic bispecifics generated from the library.
GSK biopharmaceutical research head Neil Brewis said: "GSK has an interest in rapidly assessing biology from bispecific molecules with various target combinations, and the Adimab platform fully provides us with the quality and speed we need.
"Our existing collaboration has been highly productive, and this expansion reflects our appreciation of Adimab’s capabilities and collaborative approach."
Adimab established funded discovery collaborations with 25 companies over the past five years. The firms include leading pharmaceutical companies such as Merck, Roche, Novartis, Eli Lilly, Genentech, Gilead, Kyowa Hakko Kirin and Celgene.
Image: One of the entrances to the GlaxoSmithKline factory in Ulverston, Cumbria, England. Photo: courtesy of Yohan euan o4.
